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CARD9 is a central component of anti-fungal innate
immune signaling via C-type lectin receptors, and
several immune-related disorders are associated
with CARD9 alterations. Here, we used a rare
CARD9 variant that confers protection against in-
flammatory bowel disease as an entry point to inves-
tigating CARD9 regulation. We showed that the
protective variant of CARD9, which is C-terminally
truncated, acted in a dominant-negative manner for
CARD9-mediated cytokine production, indicating
an important role for the C terminus in CARD9
signaling. We identified TRIM62 as a CARD9 binding
partner and showed that TRIM62 facilitated K27-
linked poly-ubiquitination of CARD9. We identified
K125 as the ubiquitinated residue on CARD9 and
demonstrated that this ubiquitination was essential
for CARD9 activity. Furthermore, we showed that
similar to Card9-deficient mice, Trim62-deficient
mice had increased susceptibility to fungal infection.
In this study, we utilized a rare protective allele to un-
cover a TRIM62-mediated mechanism for regulation
of CARD9 activation.
INTRODUCTION
CARD9 is a central adaptor protein in innate immune signaling
via C-type lectin receptors (CLRs), such as Dectin-1, Dectin-2,
and Mincle (Goodridge et al., 2009; Gross et al., 2006; Ishikawa
et al., 2009; Roth and Ruland, 2013; Saijo et al., 2010; Schoenen
et al., 2010; Werninghaus et al., 2009), and has more recently
been reported to regulate cytokine production induced by cyto-solic nucleic acid sensors RIG-I and Rad50 in mouse models
(Abdullah et al., 2012; Poeck et al., 2010; Roth et al., 2014).
CLRs sense components of fungal and bacterial cell walls, link-
ing signaling from these immune receptors to nuclear factor-kB
(NF-kB) activation through a series of sequential phosphoryla-
tion events. CARD9 thereby mediates production of pro-inflam-
matory cytokines, including tumor necrosis factor a (TNFa),
interleukin-6 (IL-6), and IL-1b, ultimately regulating the re-
sponses of T helper 1 (Th1) and Th17 cells (Drummond et al.,
2011; Glocker et al., 2009; LeibundGut-Landmann et al., 2007;
Marakalala et al., 2010; Robinson et al., 2009; Saijo et al.,
2010; Sokol et al., 2013).
CARD9 was recently identified as a gene associated with
determining risk for inflammatory bowel disease (IBD) (Jostins
et al., 2012; Rivas et al., 2011), ankylosing spondylitis (Pointon
et al., 2010), primary sclerosing cholangitis (Janse et al., 2011),
and immunoglobulin A (IgA) nephropathy (Kiryluk et al., 2014).
Patients with early stop codons or point mutations affecting
the N-terminal portion of CARD9 also show increased suscepti-
bility to fungal infection (Drewniak et al., 2013; Gavino et al.,
2014; Gazendam et al., 2014; Glocker et al., 2009; Grumach
et al., 2015; Herbst et al., 2015; Jachiet et al., 2015; Lanternier
et al., 2015a; Lanternier et al., 2015b; Lanternier et al., 2013;
Wang et al., 2014). Unlike most genetic risk factors for complex
diseases, CARD9 alleles exist in both predisposing and protec-
tive forms for IBD. The predisposing variant, CARD9 S12N, is
caused by a common coding SNP that was identified via
genome-wide association studies (GWASs) and is associated
with increased expression of CARD9 mRNA (Franke et al.,
2010; Jostins et al., 2012; McGovern et al., 2010; Zhernakova
et al., 2008). The protective variant, CARD9 S12ND11, is caused
by a rare splice variant in which exon 11 of CARD9 is deleted.
This allele, identified by deep sequencing of GWAS loci, results
in a protein with a C-terminal truncation and confers strong pro-
tection against disease (p < 1016) (Beaudoin et al., 2013; Rivas
et al., 2011).Immunity 43, 715–726, October 20, 2015 ª2015 Elsevier Inc. 715
The CARD9 signaling cascade is initiated after engagement of
Dectin-1 by b-glucans (which results in the phosphorylation of
Dectin-1 itself) or engagement of Dectin-2 or Mincle by fungal
mannans (which results in phosphorylation of the ITAM-contain-
ing signaling adaptor FcRg). These phosphorylation events
activate Syk kinase, which subsequently activates PKCd to
phosphorylate CARD9 at T231 (Strasser et al., 2012). Phosphor-
ylated CARD9 recruits BCL10 and MALT1 to form a CARD9-
BCL10-MALT1 (CBM) complex, which activates the canonical
NF-kB pathway (Roth and Ruland, 2013). Rubicon acts as a
feedback inhibitor by displacing CARD9 from the CBM complex
and thereby terminating CARD9-mediated signaling (Yang et al.,
2012). Interestingly, a recent report showed that Dectin-1-
CARD9 signaling induces neutrophilic myeloid-derived suppres-
sor cells; these cells functionally suppress T and natural killer
(NK) cell responses, suggesting that the CARD9 pathway might
play an important role in balancing inflammation in response to
pathogenic fungi (Rieber et al., 2015).
Aside from the kinase-dependent steps that contribute to the
initiation of the CBM signalosome and Rubicon-dependent feed-
back inhibition, little is known regarding other mechanisms that
might regulate the assembly, stability, or activity of CARD9 in
this complex. CARD9 is a scaffold protein with an N-terminal
domain composed of a CARD domain followed by two coiled-
coil domains. However, CARD9 has no clear domain within its
C terminus, and its mode of regulation is not fully defined (Hara
and Saito, 2009; Roth and Ruland, 2013).
In this study, we used disease-associated CARD9 alleles
to uncover fundamental insights into the protein-protein inter-
actions and post-translational modifications that regulate
CARD9 function. We demonstrated that the C terminus of
CARD9 is a critical regulatory module for CARD9 activity and
identified TRIM62 as a novel interactor with the CARD9 C ter-
minus. We showed that TRIM62 ubiquitinates CARD9 at K125
and demonstrated that a CARD9 alteration at this residue
(K125R) abrogates CLR-induced CARD9-mediated cytokine
production. Furthermore, Trim62/ mice showed reduced
CLR-CARD9-dependent cytokine production and increased
susceptibility to fungal infection. In parallel, we showed that
the protective CARD9 D11 variant acts in a dominant-negative
fashion for CLR-CARD9-dependent cytokine signaling and that
TRIM62-mediated ubiquitination does not occur in this variant
protein.
RESULTS
The C Terminus of CARD9 Is Essential for CARD9
Activation
The association between IBD and CARD9, which has both pro-
tective and predisposing alleles, raises the need to characterize
regulatory mechanisms for CARD9-dependent pathways. To
this end, we employed naturally occurring CARD9 variants char-
acterized by C-terminal truncations to investigate CARD9 regu-
lation. We first used a human immune cDNA panel to collect a
library of naturally occurring humanCARD9 alleles and screened
this collection for effects on CARD9-mediated cytokine produc-
tion. In addition to identifying full-length CARD9 and the disease-
associated S12N and S12ND11 alleles, we also identified several
novel variants of CARD9 (Figures 1A and S1A) and noted that the716 Immunity 43, 715–726, October 20, 2015 ª2015 Elsevier Inc.majority of the allelic variations affected the C-terminal portion of
the protein.
To definitively evaluate whether the deletion of exon 11 (D11)
imparts protection from disease, we analyzed Immunochip data-
sets with 33,311 IBD-affected individuals and 33,938 healthy
control individuals from the International Inflammatory Bowel
Disease Genetics Consortium (IIBDGC) and found that individ-
uals with the D11 splice variant are less likely to develop IBD
regardless of the presence of S12N alteration (Figure S1B),
further suggesting an important functional role for the C terminus
of CARD9.
To examine how C-terminal truncation affects CARD9 func-
tion, we stimulated CARD9-dependent pathways by using either
depleted zymosan, a glucan-enriched preparation that is derived
from fungal cell walls and mainly activates Dectin-1 (Gross et al.,
2006), or trehalose 6,6-dimycolate (TDM), a mycobacterial cell-
wall component that activates two other CLRs: Mincle and
macrophage C-type lectin (Miyake et al., 2013; Roth and Ruland,
2013; Werninghaus et al., 2009). Activation by these two ligands
led to CARD9-dependent production of proinflammatory cyto-
kines, including TNFa and IL-6 (Figure S1C) (Gross et al., 2006;
Saijo et al., 2010; Werninghaus et al., 2009). We therefore re-ex-
pressed human CARD9 isoforms in murine Card9/ bone-
marrow-derived dendritic cells (BMDCs) and assessed cytokine
production in response to these ligands by ELISA (Figures 1B–1E
and S1D–S1F). BMDCs expressing the predisposing variant
CARD9 S12N showed greater TNFa and IL-6 production than
BMDCs expressing wild-type CARD9. In contrast, CARD9 D11
and CARD9 S12ND11, as well as the C-terminally truncated
CARD9 V6, showed significant impairment in TNFa and IL-6 pro-
duction. This effect did not occur when cytokine production was
stimulated by lipopolysaccharide (LPS), a ligand for Toll-like re-
ceptor 4 (TLR4), indicating that the impairment was specific to
the CARD9 pathway (Figures 1D and S1E). These data suggest
that the C terminus of CARD9 is required for CLR-CARD9-medi-
ated cytokine production.
A Protective CARD9 Variant Acts in a Dominant-
Negative Manner
Pursuing our finding that CARD9 D11 demonstrates loss of
CARD9 function (Figure 1), we next examined whether this
variant would have a dominant-negative effect on CARD9 func-
tion when co-expressed with wild-type CARD9 in human cells.
To test this hypothesis, we expressed CARD9 D11 in the human
monocytic cell line THP-1, as well as in primary human mono-
cyte-derived dendritic cells (MDDCs), and found that CARD9
D11 suppressed depleted zymosan-induced NF-kB activation
in THP-1 cells (Figures 2A and 2B) and depleted zymosan-
induced TNFa production in MDDCs (Figures S2A and S2B).
Consistent with these findings, we also expressed CARD9 D11
in wild-type murine BMDCs and found that CARD9 D11 inhibited
TDM-induced TNFa and IL-6 production (Figures S2C and S2D).
In contrast, LPS-induced cytokine production was unaltered un-
der the same experimental conditions in both human MDDCs
and murine BMDCs (Figures S2E and S2F). Collectively, the re-
sults indicate that CARD9 D11 has a dominant-negative effect
in both human and mouse dendritic cells. Furthermore, FLAG-
tagged human CARD9 D11 co-immunoprecipitated with endog-
enous CARD9 in wild-type murine BMDCs (Figure 2C). This
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Figure 1. C-Terminal CARD9 Truncations Impair Depleted Zymosan- and TDM-Induced Cytokine Production
(A) Schematic of CARD9 variants used. All indicated variants, with the exception of CARD9 416–536 (which was designed for experimental use), were found in a
human immune cDNA panel. CC, coiled-coil domain.
(B–D)Card9/murine BMDCs transduced with the indicated CARD9 variants were stimulated with depleted zymosan, TDM, or LPS, and cytokine amounts were
assessed by ELISA. Data were obtained from three independent experiments performed in duplicate (n = 3 mice per experiment).
(E) Expression of CARD9 variants in total lysates from (B)–(D) as detected by western blot. Bars represent means ± SD. *p < 0.05, **p < 0.01. Comparisons in
(B)–(D) are relative to stimulated wild-type (WT) CARD9.
See also Figure S1.result demonstrates that CARD9 D11 can form a complex with
endogenous full-length CARD9, suggesting that CARD9 D11
might inhibit CARD9 function via hetero-oligomerization with
full-length CARD9. To pursue these findings, we developed an
ELISA-based assay that detects the interaction between differ-
entially tagged purified CARD9 proteins in vitro in a cell-free
system. By using GST- and FLAG-tagged purified CARD9 con-
structs, we confirmed that both wild-type CARD9 and CARD9
D11 are capable of directly interacting with CARD9. Importantly,
the ability of CARD9 D11 to form complexes with wild-type
CARD9 was not impaired (Figure 2D).
TRIM62 Binds the C Terminus of CARD9
Because CARD9 functions as a scaffold protein, we next inves-
tigated whether loss of specific protein-protein interactions by
C-terminally truncated proteins might underlie their effects on
CARD9 function. Because the details of how the C terminus of
CARD9 delivers signals from receptors to effectors are largely
unknown, we sought to identify novel CARD9 binding partners
that might be responsible for the loss of signal transduction in
the truncated proteins. To this end, we re-expressed a tagged
version of wild-type CARD9 in immortalizedCard9/ cells (Blasiet al., 1985) and employed tandem affinity purification to purify
CARD9. Using mass spectrometry, we identified TRIM62 as a
top hit co-purified with CARD9 on the basis of high peptide
counts and a high percentage of protein coverage.
Members of the TRIM family of proteins are involved inmultiple
cellular processes, including innate immunity (Uchil et al., 2013;
Versteeg et al., 2013), and mutations in multiple TRIM-encoding
genes are associated with human disease (Marı´n, 2012; McNab
et al., 2011). However, most studies of TRIM proteins have em-
ployed overexpression or knockdown approaches (Arimoto
et al., 2010; Tsuchida et al., 2010; Uchil et al., 2013; Versteeg
et al., 2013), and very few studies in knockout mice or human
cells have examined ligand specificity (Gack et al., 2007; Zhang
et al., 2013). We next examined whether we could detect a direct
interaction between CARD9 and TRIM62. To demonstrate
TRIM62 binding of CARD9, we developed an ELISA-based sys-
tem that employs differentially tagged CARD9 and TRIM62.
These experiments demonstrated that wild-type CARD9, but
not CARD9 D11, interacted with TRIM62, as assessed by
CARD9-TRIM62 ELISA. Addition of purified C-terminal domain
(CTD) of CARD9 abrogated this interaction, supporting the
hypothesis that TRIM62 binds the C terminus of CARD9Immunity 43, 715–726, October 20, 2015 ª2015 Elsevier Inc. 717
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Figure 2. CARD9 D11 Is a Dominant-Nega-
tive Variant
(A) THP-1 cells were transduced with wild-type
(WT) FLAG-CARD9 or FLAG-CARD9 D11 and
stimulatedwithdepleted zymosan.NF-kBamounts
were assessed by NF-kB luciferase assay.
(B) A western blot shows expression of CARD9 as
detected by antibodies against endogenous
CARD9 (top) or FLAG (bottom) in lysates from (A).
Note that the antibody detecting endogenous
CARD9 has an N-terminal epitope and therefore
does not recognize CARD9 D11.
(C) WT BMDCs were transduced with FLAG-
StrepII empty vector or FLAG-StrepII-tagged
CARD9D11 and then immunoprecipitated for
tagged CARD9 D11.
(D) Purified FLAG-tagged WT CARD9 and CARD9
D11 were incubated with immobilized GST-
CARD9; interactions were assessed by ELISA.
Coomassie gel on the right shows purified pro-
teins used in the ELISA.
See also Figure S2.(Figure S3A). To further study the molecular interaction between
CARD9 and TRIM62 and the dominant-negative effect of CARD9
D11, we developed a cell-based BRET (bioluminescence reso-
nance energy transfer) system that enables detection of specific
protein-protein interactions in the context of an intact cell. BRET
has been used for characterizing disease-related genetic vari-
ants of GNAL (Fuchs et al., 2013), as well as for investigating
the function of cancer-associated PTEN alterations in a domi-
nant-negative context (Papa et al., 2014). Notably, a BRET assay
was recently used for discovering a novel CARD9 interactor in a
physiologic setting (Roth et al., 2014). In our BRET system, nano-
luciferase-tagged CARD9 (donor) can interact with Halo-tagged
TRIM62 (acceptor) to generate energy measured as a BRET
signal (Figure S3B). We first confirmed that the assay robustly
detects an interaction between CARD9 and TRIM62. In agree-
ment with our findings that the interaction is mediated by the C
terminus of CARD9, we found that the interaction can be
competitively disrupted by co-expression of the CARD9 C termi-
nus (amino acids 416–536) (Figure S3C). To more precisely
examine the dominant-negative effect of CARD9 D11, we as-
sessed the interaction between CARD9 and TRIM62 in the
presence of co-expressed CARD9 D11 or negative controls
such as unrelated proteins SULT1 and LacZ (Figure S3D). The
presence of CARD9 D11 disrupted the CARD9-TRIM62 interac-
tion, whereas SULT1, LacZ, or vector alone showed no effect.
These results demonstrate the inhibitory effect of the protective
variant on the CARD9-TRIM62 interaction and support the
hypothesis that hetero-oligomerization of wild-type CARD9
and CARD9 D11 might functionally inhibit signaling of wild-type
CARD9.
Consistent with these findings, co-immunoprecipitation
studies of CARD9 and TRIM62 demonstrated that CARD9 D11,
CARD9 S12ND11, and CARD9 V6 failed to bind TRIM62,
whereas the CARD9 C terminus alone (amino acids 416–536)
bound TRIM62 even more efficiently than full-length wild-type
CARD9 (Figure 3A). We further confirmed these results by718 Immunity 43, 715–726, October 20, 2015 ª2015 Elsevier Inc.demonstrating that endogenous CARD9 interacted with endog-
enous TRIM62 in a zymosan-dependent manner in THP-1 cells
(Figure S3E). These results demonstrate that these proteins
interact endogenously in an activation-dependent manner.
Having found a biochemical interaction between TRIM62 and
CARD9, we next examined their colocalization by immunofluo-
rescence. We found that TRIM62 co-localized with wild-type
CARD9 and CARD9 S12N but did not co-localize with CARD9
variants lacking the C terminus (CARD9 D11, CARD9 S12N
D11, or CARD9 V6) in HeLa cells (Figures S3F–S3H); all isoforms
of CARD9 showed relatively diffuse cytoplasmic localization
when expressed alone, whereas TRIM62 showed a diffuse local-
ization with some cytoplasmic bodies, consistent with localiza-
tion patterns observed for TRIM5a (Campbell et al., 2007) and
TRIM22 (Reymond et al., 2001) (Figures S3F–S3H). Consistent
with these observations, endogenous CARD9 and TRIM62 co-
localized in a zymosan-dependent manner in wild-type BMDCs
(Figures 3B and 3C).
Furthermore, using THP-1 cells in which endogenous CARD9
had been deleted with CRISPR, we re-expressed tagged wild-
type CARD9 or CARD9 D11 and found that although wild-type
CARD9 colocalized with endogenous TRIM62 in a stimulation-
dependent manner, CARD9 D11 did not (Figures 3D and 3E).
Notably, TRIM62 co-localized with BCL10, a well-characterized
CARD9 interactor, in a zymosan-dependent manner in wild-type
BMDCs, suggesting that TRIM62 might associate with CARD9
as part of the CBM complex (Figures S3I and S3J).
TRIM62 Induces K27-Linked CARD9 Ubiquitination
We next examined the functional consequences of the CARD9-
TRIM62 interaction. TRIM family proteins generally modify their
targets via E3 ligase activity, which can include ubiquitination,
SUMOylation, or ISGylation (Chu and Yang, 2011; McNab
et al., 2011). We found that TRIM62 specifically promoted
CARD9 ubiquitination in HEK293T cells (Figure 4A) and
confirmed that endogenous CARD9 was ubiquitinated in a
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B Figure 3. TRIM62 Interacts with Full-Length
CARD9, but Not CARD9 C-Terminal Trunca-
tions
(A) HEK293T cells were transfected with the indi-
cated constructs and then immunoprecipitated for
tagged CARD9.
(B) Wild-type (WT) BMDCs were stimulated with
depleted zymosan and stained for endogenous
CARD9 and TRIM62. Scale bars represent 5 mm.
(C) Quantification of results shown in (B).
(D) CARD9/ THP-1 cells were transduced with
V5-tagged WT CARD9 or CARD9 D11 and stimu-
lated with depleted zymosan. Cells were stained
for endogenous TRIM62 and tagged CARD9.
(E) Quantification of results shown in (D).
See also Figure S3.stimulation-dependent manner in dendritic cells (Figure 4B). We
next designed an E3-ligase-dead variant of TRIM62 by changing
two conserved catalytic cysteines in the RING domain to alanine
(TRIM62 C11A;C14A) (Deshaies and Joazeiro, 2009) and
showed that CARD9 ubiquitination was dependent on E3 ligase
activity in HEK293T cells (Figure 4C). Importantly, CARD9 D11
was not ubiquitinated by TRIM62 (Figure 4D). Similarly to wild-
type TRIM62, TRIM62 C11A;C14A colocalized extensively with
CARD9 (Figure S4).
Next, we identified which type of ubiquitin linkage was occur-
ring on CARD9 and showed that ubiquitination was dramatically
reduced by a K27R alteration in ubiquitin (Figure 4E). In a
reciprocal assay using ubiquitin mutants that each contained
only one lysine, we found that K27 alone was sufficient for
TRIM62-mediated ubiquitination of CARD9 (Figure 4F). Alto-Immunity 43, 715–726,gether, we conclude that TRIM62 medi-
ates K27-linked ubiquitination of full-
length CARD9, but not CARD9 D11.
CARD9 Ubiquitination by TRIM62
Plays a Critical Role in CLR-CARD9
Signaling
To identify the specific CARD9 lysine
target or targets ubiquitinated by
TRIM62, we first examined all 40 lysines
in human CARD9. We identified 17 of
these lysines as being absolutely
conserved across 17 mammalian species
and elected to individually change each of
these residues to arginine. We found that
alteration of K125 significantly reduced
TRIM62-mediated CARD9 poly-ubiquiti-
nation in HEK293T cells (Figure 5A).
Importantly, using in vitro ubiquitination
assays with purified proteins, we verified
that CARD9 was directly ubiquitinated
by TRIM62 at residue K125; this ubiquiti-
nation was dependent on the ligase activ-
ity of TRIM62 and did not occur in CARD9
D11 (Figure 5B).
To identify the functional consequence
of this ubiquitination, we re-expressedthis ubiquitination-deficient CARD9 in Card9/ BMDCs. We
found that K125R abolished CARD9-mediated cytokine produc-
tion upon depleted zymosan or TDM stimulation (Figures S5A–
S5D), indicating that ubiquitination of CARD9 K125 is critical
for CARD9 activation. Similar results were obtained in human
CARD9/ THP-1 cells reconstituted with wild-type CARD9 or
CARD9 K125R. In this system, we found that stimulation-depen-
dent NF-kB activity was dramatically reduced by the introduc-
tion of K125R (Figures 5C and 5D). Notably, in Card9/ BMDCs
reconstituted with wild-type CARD9 or CARD9 K125R, both the
wild-type and altered forms of CARD9 retained zymosan-depen-
dent colocalization with BCL10 (Figures S5E and S5F). However,
the CARD9-BCL10 interaction remained unproductive in the
context of K125R, as shown by the disruption of NF-kB activity
by this alteration. Taken together, these results demonstrateOctober 20, 2015 ª2015 Elsevier Inc. 719
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Figure 4. TRIM62 Promotes the Ubiquitination of Full-Length CARD9, but Not CARD9 Truncations
(A) HEK293T cells were transfected with indicated constructs, immunoprecipitated for tagged CARD9, and then blotted for tagged ubiquitin, SUMO1, SUMO2,
SUMO3, and ISG15.
(B) Wild-type (WT) BMDCs were stimulated with depleted zymosan, immunoprecipitated for CARD9, and then blotted for endogenous CARD9 and ubiquitin.
(C) HEK293T cells were transfected with indicated constructs, immunoprecipitated for tagged CARD9, and then blotted for ubiquitin in the presence of either WT
or a ligase-dead (C11A;C14A) version of TRIM62.
(D) HEK293T cells were transfected with indicated constructs, immunoprecipitated for tagged CARD9, and then blotted for tagged ubiquitin.
(E and F) HEK293T cells were transfected with indicated constructs, immunoprecipitated for tagged CARD9, and then blotted for indicated ubiquitin mutants. In
(E), transfected ubiquitin constructs have single point alterations in the indicated lysine residues. In (F), transfected ubiquitin constructs have point alterations in
multiple lysines, leaving only the indicated lysine residue intact. FS, FLAG-StrepII.
See also Figure S4.
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Figure 5. TRIM62-Mediated CARD9 Ubiquitination at K125 Is Critical for CARD9 Activation
(A) HEK293T cells were transfected with TRIM62, ubiquitin (K27 only), and CARD9 with the indicated point alterations and then immunoprecipitated for CARD9.
(B) The indicated proteins were purified and incubated in vitro for assessing ubiquitination of CARD9.
(C) CARD9/ THP-1 cells were reconstituted with wild-type (WT) CARD9, CARD9 D11, or CARD9 K125R and stimulated with depleted zymosan, and NF-kB
amounts were assessed by NF-kB luciferase assay.
(D) A western blot shows expression levels of CARD9 in the cells used in (C).
See also Figure S5.that K125-mediated ubiquitination is critical for CARD9-medi-
ated NF-kB signaling.
TRIM62 Regulates Immune Responses and
Susceptibility to Candida albicans Infection In Vivo
To directly assess whether the novel CARD9 interactor TRIM62
is important for immune responses elicited via the CARD9
signaling pathway, we generated Trim62/ mice (Figures S6A
and S6B). Intravenous injection of heat-killed C. albicans,
a fungal pathogen that activates the CLR-CARD9 pathway,
induced acute, systemic IL-6 production, which was significantly
impaired in the absence of TRIM62 (Figure 6A).
To examine pathways involved in pro-inflammatory cytokine
production, we used intracellular staining and flow cytometry
to measure activity of both NF-kB and mitogen-activated
protein kinase (MAPK) pathways, given that a recent study
in macrophages identified a role for ERK signaling in suscepti-
bility to Candida (Jia et al., 2014). Isolated wild-type and
Trim62/ splenic dendritic cells were stimulated ex vivo for
10 min with LPS or heat-killed C. albicans. Consistent with
the in vivo findings, Trim62/ dendritic cells had less phos-
phorylated IkBa and ERK1/2 in response to heat-killed
C. albicans stimulation, indicating impaired NF-kB and MAPK
signaling, respectively (Figure S6C). This difference was not
observed in response to LPS, indicating that the impaired
signaling was specific to the CLR-CARD9 signaling pathway.
These results are in agreement with a recent report showing
that TRIM62 knockdown in human primary macrophages did
not affect MyD88-dependent signaling at early time points
(Uchil et al., 2013).
In addition to observing impaired proinflammatory pathway
activation and cytokine production in response to heat-killedC. albicans, we found by using live C. albicans infection that
Trim62/ mice had significantly more C. albicans colony-form-
ing units (CFUs) present in the kidney, spleen, and liver (Fig-
ure 6B), suggesting impaired pathogen clearance. To determine
whether the increased fungal burden in Trim62/ mice after
in vivo infection was due to defective phagocytosis, we exposed
bone-marrow-derived macrophages (BMDMs) to fluorescently
labeled C. albicans and determined uptake via flow cytometry.
Uptake of C. albicans was comparable in wild-type and
Trim62/ mice, indicating that the enhanced fungal burden in
Trim62/ mice was not due to differences in phagocytosis effi-
ciency (Figure 6C). Additionally, expression of cytokines and
chemokines important during C. albicans infection was signifi-
cantly lower in Trim62/ mice than in wild-type mice, suggest-
ing that downstream inflammatory signaling events (through the
TRIM62-CARD9 pathway) are blunted (Figure S6D). Lastly, to
determine whether the decreased cytokine responses and
increased fungal burden in Trim62/mice after infection confer
enhanced susceptibility to C. albicans, we monitored mice over
time after in vivo infection. Strikingly, and consistent with the
above data, Trim62/ mice were more susceptible to in vivo
C. albicans infection, such that they showed 100% mortality by
day 15 after infection (Figure 6D).
Given the association between this pathway and IBD, we also
assessed Trim62/ mice in the dextran sulfate sodium (DSS)
model of intestinal inflammation. As in previously published
studies in Card9/ mice, compared to wild-type mice treated
with DSS, Trim62/ mice showed increased weight loss,
greater inflammation, and impaired cytokine responses (Figures
S6E–S6G). Taken together, these results demonstrate that
TRIM62 is important for immunity in in vivo models of
C. albicans infection and DSS-induced colitis.Immunity 43, 715–726, October 20, 2015 ª2015 Elsevier Inc. 721
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Figure 6. TRIM62 Regulates Immune Responses and Susceptibility to C. albicans Infection In Vivo
(A) Wild-type (WT) and Trim62/ mice were injected i.v. with heat-killed C. albicans, and serum IL-6 amounts were quantified 4 hr later by ELISA (n = 5). Bars
display IL-6 relative to WT amounts.
(B) WT and Trim62/ mice were injected with C. albicans, and fungal loads in the kidney, spleen, and liver were assessed 3 and 6 days after infection.
(C) WT and Trim62/ BMDMs were incubated with pHrodo-labeled C. albicans, and phagocytosed C. albicans was quantified by intracellular fluorescence via
flow cytometry.
(D) A survival curve shows the percentage of survival over time in WT and Trim62/ mice infected with C. albicans. Bars represent means ± SD. *p < 0.05.
See also Figure S6.DISCUSSION
CARD9 coding mutations are associated with multiple immune-
related diseases, underscoring the physiologic importance of
CARD9 signaling in immunity. In the current study, we used a
CARD9 allele strongly protective against IBD as an entry point
to uncovering basic insights into the biology of CARD9 regula-
tion, as well as a potential mechanism for the protective effect
of the D11 variant. Through systematic pathway mapping, we
found a CARD9 C-terminal interacting partner that regulates
CARD9 function in a ligand-specific manner; this interactor
(TRIM62), which does not interact with the protective variant of
CARD9, acts as an E3 ubiquitin ligase to activate CARD9 func-
tion. Given our findings that TRIM62 acts as a restriction factor
for fungal infections, our results expand the list of E3 ligases
that function as restriction factors and extend the range of path-
ogens implicated in TRIM family signaling. The TRIM family of
proteins expanded relatively recently in evolution (Ozato et al.,
2008) and play important roles in the crosstalk between the
innate and adaptive immune systems (Rajsbaum et al., 2014a).
The majority of studies of TRIM proteins have focused on their
roles as antiviral restriction factors (Ozato et al., 2008), and
recent screens have reported that mRNA and localization of
most known TRIM proteins are altered during viral infection
(Uchil et al., 2013; Versteeg et al., 2013). Extending these
studies, a recent report identified that TRIM5 is a regulator of
autophagy and acts as a restriction factor against HIV-1 (Mandell
et al., 2014). TRIM family members largely function in negative
regulatory circuits, as was recently demonstrated for TRIM9, a
negative regulator of NF-kB pro-inflammatory cytokine signaling
(Shi et al., 2014). An increasing number of TRIM proteins have
also been described as enhancers of innate immune pathways,
as in the case for TRIM44, which stabilizes MAVS to enhance
signaling (Yang et al., 2013). TRIM proteins mediate several
types of ubiquitin linkages, and most studies focus on K48-
and K63-based linkages and their respective roles in degrada-
tion and stabilization of protein complexes (Davis and Gack,
2015; Flannick et al., 2014; Gack et al., 2007; Rajsbaum et al.,
2014b; Tsuchida et al., 2010; Zhao et al., 2012), although K27-
linked ubiquitination has been reported for TRIM23 (Arimoto722 Immunity 43, 715–726, October 20, 2015 ª2015 Elsevier Inc.et al., 2010). Our findings of TRIM62-mediated K27-linked ubiq-
uitination of CARD9 suggest that this type of linkage promotes
an important mechanism for protein activation, although notably
the K125R alteration does not affect colocalization of CARD9
and BCL10.
To date, all clinically reported homozygous or compound-het-
erozygous carriers with either no CARD9 expression or CARD9
loss of function are more susceptible to fungal infection (Drew-
niak et al., 2013; Gavino et al., 2014; Gazendam et al., 2014;
Glocker et al., 2009; Grumach et al., 2015; Herbst et al., 2015;
Jachiet et al., 2015; Lanternier et al., 2015a; Lanternier et al.,
2015b; Lanternier et al., 2013; Wang et al., 2014). Our results
from Trim62/ mice suggest that TRIM62-mediated regulation
of CARD9 activation is critical in the context of fungal infection.
These data complement previous studies reporting critical
roles for CARD9 and PKCd during C. albicans infection and sug-
gest that TRIM62 is a novel member of this pathway and is
important for anti-fungal immunity (Gross et al., 2006; Strasser
et al., 2012). Furthermore, we found that Trim62/mice, similar
to Card9/ mice, are more susceptible to DSS colitis, under-
scoring the importance of this pathway in intestinal homeostasis
and fortifying previous reports on the relationship between fungi
and IBD (Chehoud et al., 2015; Richard et al., 2015; Romani,
2011).
Next-generation sequencing has identified both a common
predisposing allele and rare protective splice variant in CARD9
(Rivas et al., 2011). The presence of both common and rare
risk variants in a single gene has nowbeen increasingly observed
in multiple studies, advancing the concept that when multiple
common and rare variants are discovered, the resulting allelic
series can serve to anchor a dose-response relationship be-
tween gene and disease. For example, the connection between
rare genetic variants and therapeutic advances has been well
demonstrated by PCSK9 in modulating amounts of low-density
lipoprotein cholesterol, where protective variation can be thera-
peutically mimicked (Cohen et al., 2006), and a recent finding of
SLC30A8 loss-of-function mutations that protect against type 2
diabetes (Flannick et al., 2014). Our findings demonstrate that
the protective CARD9 variant does not undergo ubiquitination
by TRIM62, and we propose that the protective effect of
the C-terminal truncation might be mediated by loss of TRIM62
interaction and thereby limit proinflammatory cytokine re-
sponses. Given that TRIM62-dependent ubiquitination and
subsequent activation of CARD9 might be targetable, these
findings suggest a model in which a naturally occurring pro-
tective allele might be used as a guide for rational design of
therapeutics. Indeed, evolution has ‘‘validated’’ this approach
as a safe and effective strategy for decreasing the likelihood of
developing IBD.
EXPERIMENTAL PROCEDURES
Plasmids
For lentiviral vectors, FLAG-StrepII fusion human CARD9 variants were
constructed by PCR-based subcloning of CARD9 coding sequences into
a lentivirus-based CSGW vector backbone (gift from Christian Mu¨nz,
University of Zurich). For other CARD9 constructs, CARD9 was cloned
into either a pCMV vector (see section ‘‘CARD9 Variant Cloning’’ in the
Supplemental Experimental Procedures) or pcDNA4/TO-FLAG-StrepII.
Ubiquitin cDNA was kindly provided by Dr. M. Scheffner (University of Kon-
stanz, Germany). All other genes were originally obtained from either
OpenBiosystems or Origene and subcloned into indicated tagged vectors
by PCR. Wild-type and altered ubiquitin, SUMO1, SUMO2, SUMO3, and
ISG15 were subcloned into pCMV-3xMyc. pCMV-3xHA and pCMV-3xMyc
were derived from pCMV-Myc (Clontech). TRIM62 constructs were subcl-
oned into either pCMV-3xHA or pcDNA4/TO-V5. pcDNA4/TO-FLAG-StrepII
and pcDNA4/TO-V5 were derived from pcDNA4/TO (Invitrogen). FLAG-
StrepII, HA, and Myc are all N-terminal tags. All cDNAs were confirmed by
DNA sequencing.
Chemical Reagents
Depleted zymosan was purchased from Invivogen. Trehalose 6,6’-dimycolate
(TDM) was obtained from Enzo Life Sciences. TDM was dissolved in 1 mg/ml
chloroform, methanol, and water at a 90:10:1 ratio and further diluted with iso-
propanol. LPS was purchased from Sigma or Invivogen.
Cell Culture and Lentiviral Production
HEK293T and HeLa cells were maintained at 37C and 5%CO2 in DMEM sup-
plemented with 10% fetal calf serum and 15 mg/ml gentamycin sulfate. THP-1
cells were maintained at 37C and 5% CO2 in RPMI1640 supplemented with
10% fetal calf serum, 5 3 104M beta-mercaptoethanol, and 15 mg/ml genta-
mycin sulfate. For preparing lentivirus for infection, protocols from the Broad
Institute’s RNAi Consortium shRNA Library were used (http://www.
broadinstitute.org/rnai/trc/lib). The Lentivirus qPCR Titer Kit (Applied Biolog-
ical Materials) was used for lentiviral titration. pSIV3+ plasmid for generating
Vpx-VLP was a gift from Dr. Andrea Cimarelli (E´cole Normale Supe´rieure de
Lyon, France) (Berger et al., 2011).
Trim62–/– Mouse Strain
Trim62-heterozygous mice on the 129/SvEv genetic background were pur-
chased from Taconic (catalog no. TF2743). Trim62-heterozygous mice,
derived from an F1 generation of the Trim62-heterozygous mice from
Taconic and C57BL/6 mice with wild-type Trim62, were bred for generating
wild-type or Trim62/ littermates. The targeted locus is located at the junc-
tion of the first exon and first intron of Trim62, resulting in deletion of a
portion of the exon 1 coding region and intron 1 of Trim62. See also Fig-
ure S6. Trim62/ mice are viable and born at Mendelian ratios.
Preparation of Heat-Killed C. albicans
C. albicans strain SC5314 (ATCC MYA-2876) was obtained from Eleftherios
Mylonakis (Massachusetts General Hospital, Boston). C. albicans were
harvested from an overnight culture in YPD medium (Y1375, Sigma) at
30C. C. albicans were washed with PBS twice and resuspended in PBS at
2 3 108/ml. Resuspended C. albicans were then incubated for 2 hr at 68C
and cooled on ice. Heat-killed cell death was verified by cell plating on YPD
agar plates.In Vivo Injection of Heat-Killed C. albicans
1 3 107 heat-killed C. albicans in PBS were injected intravenously (i.v.). After
4 hr, serum was harvested, and IL-6 amounts were determined via ELISA.
Ex Vivo Splenic DC Stimulations and Intracellular Phosphoprotein
Staining
CD11c+ cells were positively selected from the spleen with MACS technology
according to the manufacturer’s (Miltenyi Biotec) protocol. 1 3 106 cells were
resuspended in complete RPMI (10% fetal bovine serum and 15 mg/ml genta-
micin) and incubated for 10 min at 37C with 5% CO2 in one of three condi-
tions: (1) no stimulation, (2) 100 ng/ml LPS stimulation, or (3) 13 106 heat-killed
C. albicans stimulation. Cells were immediately fixed with BD Cytofix Fixation
Buffer and permeabilized with BD Phosflow Permeabilization Buffer 3 accord-
ing to the manufacturer’s (BD Biosciences) protocol. After 20 min of Fc block
on ice, cells were stained as indicated with the following antibodies: CD11c-
PECy7 (BD Biosciences), phospho-ERK1/2-PE (BD Biosciences), phospho-
IkBa (Cell Signaling Technologies), and donkey anti-rabbit IgG DyLight 488
(BioLegend). Cells were acquired on the BD FACSVerse (BD Biosciences)
and analyzed with FlowJo Software.
C. albicans for In Vivo Infection
C. albicans (strain ATCC 90028) were grown on yeast-peptone-dextrose agar
(Difco) at 30C. For each infection, a fresh culture of C. albicans was started
from 80C stocks. For experiments, a fresh colony was isolated from an
agar plate and grown in YPDmedia for 24 hr at 30C. Prior to inoculation, yeast
cells were washed three times in PBS, counted, and adjusted to the appro-
priate concentration.
Viable C. albicans Counts
Mice were infected i.v. with 105C. albicans and sacrificed on days 3 and 6 after
infection. CFUs of C. albicans in the homogenized kidney, spleen, and liver
were determined by plate counts. Data are expressed as CFU permg of tissue.
Mice
Card9/ mice have been previously described (Hara et al., 2007). Mice were
maintained in specific-pathogen-free facilities at Massachusetts General
Hospital. All animal studies were conducted under protocols approved by
the Institutional Animal Care and Use Committee (IACUC) at Massachusetts
General Hospital.
Statistical Analysis
Unpaired two-tailed Student’s t tests were used for comparisons for ELISA. All
statistical comparisons were made between multiple independent experi-
ments performed in parallel.
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